LLWM
DNLI icon

Life Line Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Life Line Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,812
Closed -$228K – 26
2024
Q3 		$228K Buy
+7,812
New +$194K 0.08% 23

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Life Line Wealth Management's DNLI Position: Q4 2024 in Review

Life Line Wealth Management sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 7,812 shares — an estimated $228K sold.

Life Line Wealth Management first reported a position in DNLI in Q3 2024 and held it in 1 quarter. The position peaked at $228K in Q3 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • Life Line Wealth Management reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Life Line Wealth Management sold 7,812 Denali Therapeutics shares in Q4 2024, an estimated $228K.
  • Life Line Wealth Management first reported a position in Denali Therapeutics in Q3 2024 and held it in 1 quarter.
  • Life Line Wealth Management's Denali Therapeutics position peaked at $228K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Life Line Wealth Management's 13F filing for Q4 2024, filed 25 Mar 2025.